Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 7 is a conjugate consisting of a Thalidomide-derived E3 ligase ligand and a specific linker. This compound functions primarily by recruiting the Cereblon (CRBN) protein, making it a critical intermediate in the synthesis of complete proteolysis-targeting chimeras (PROTACs). It is ideal for applications in targeted protein degradation research and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-CH2-CO-NH-C2-PEG2-NH-Boc is an E3 ligase ligand-linker conjugate that incorporates a thalidomide-based cereblon ligand and a PEG linker. This compound serves as a critical building block for the development of PROTAC degraders, facilitating targeted protein degradation. Its utility in chemical biology and drug discovery is significant, particularly in studies aimed at elucidating protein function and therapeutic responses. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG1-OTs is a conjugate designed as a ligand for E3 ligases, facilitating targeted protein degradation. This compound serves as a versatile building block for the synthesis of various targeted degradation compounds, including YD54. Its application in chemical biology and drug discovery makes it a valuable tool for investigating E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-PEG3-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound features the (S,R,S)-AHPC ligand, which selectively targets von Hippel-Lindau (VHL) E3 ligases, and is equipped with a three-unit polyethylene glycol (PEG) linker to enhance solubility and target specificity. It is suitable for facilitating the degradation of target proteins in research applications related to protein homeostasis and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-6-F-5-pip-CHO is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis targeting chimeras (PROTACs). This compound serves as a key component in the synthesis of targeted protein degraders, enabling selective modulation of protein levels within cells. Its application extends to studies in targeted therapy and drug discovery, facilitating innovative approaches in cancer research and beyond. -
Ligand for E3 Ligase
Pomalidomide-CO-C5-azide is a bioorthogonal ligand designed for E3 ligase interaction. This compound enables the synthesis of proteolysis-targeting chimeras (PROTACs), which demonstrate promising anticancer activity. It serves as a valuable tool for researchers developing targeted therapies that utilize the ubiquitin-proteasome system to selectively degrade oncogenic proteins. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C4-NH2 is an E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand attached to a versatile linker for use in PROTAC technology. This compound facilitates targeted protein degradation by recruiting E3 ligases, enabling the selective degradation of proteins involved in various diseases. Its application in research may enhance the development of innovative therapeutic strategies and provide insights into protein regulation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 50 is a conjugate comprising an E3 ligase ligand, (S,R,S)-AHPC, and a corresponding linker. The (S,R,S)-AHPC is derived from the VH032 structure and functions as a selective ligand for von Hippel-Lindau (VHL) proteins, facilitating targeted protein degradation. This conjugate serves as a crucial intermediate in the synthesis of complete PROTAC molecules, enabling applications in drug discovery and development aimed at modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand 29-azacyclohexane-O-cyclohexane-CO is a synthetic E3 ligase ligand-linker conjugate designed for the development of PROTACs. It facilitates the synthesis of PROTAC LRRK2 Degrader-3, a potent degrader of LRRK2 that exhibits significant anti-neuroinflammatory properties. This compound is essential for research applications focused on targeted protein degradation and neuroinflammatory pathways. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG6-Tos is an E3 ligase ligand-linker conjugate that combines a von Hippel-Lindau (VHL)-recruiting ligand with a PEGylated linker featuring a tosyl group. The tosyl moiety serves as a proficient leaving group for nucleophilic substitution reactions. This compound is particularly valuable for the synthesis of PROTAC (Proteolysis Targeting Chimeras) compounds, facilitating targeted protein degradation in various research applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C2-COOH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a VHL ligand with a linker structure derived from (S,R,S)-AHPC, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). Its primary utility lies in enabling specific ubiquitination of target proteins for research into protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C2-OH is an E3 ligase ligand-linker conjugate that combines a cereblon (CRBN) ligand with a flexible linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation in various biological systems. Its unique structure supports studies in protein homeostasis and therapeutic applications in cancer research and beyond. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-C4-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to enhance protein degradation pathways. It features a VHL ligand and a customized linker based on (S,R,S)-AHPC structure. This compound is suitable for the synthesis of PROTACs, facilitating targeted protein degradation research and applications in drug development. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 132 is an intermediary conjugate composed of an E3 ligase ligand and a linker, designed for the synthesis of PROTAC molecules. This compound facilitates targeted protein degradation, offering insights into the modulation of protein levels in cellular systems. Its primary research applications include enhancing the understanding of protein-protein interactions and developing novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azacyclohexane is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand critical for targeted protein degradation. This compound is designed for the synthesis of PROTACs, enabling selective modulation of protein levels in cellular systems. Its unique structure supports research into targeted therapies and the mechanistic understanding of protein regulation in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-5-bromopentanamide is an E3 ligase ligand-linker conjugate that combines the CRBN ligand Lenalidomide with a 5-bromopentanoyl linker. This compound is essential for the synthesis of PROTACs, which facilitate targeted protein degradation in cellular systems. Its application is pivotal in drug discovery and development, particularly in exploring the therapeutic potential of novel degraders in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-piperidine is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a linker structure. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), thereby enabling targeted protein degradation in cellular systems. It is valuable for investigative studies aimed at elucidating cellular mechanisms and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound integrates a VHL ligand with a (S,R,S)-AHPC-based linker, facilitating the synthesis of PROTAC molecules. Its unique design enables efficient engagement with E3 ligases, making it a valuable tool for researchers investigating innovative therapeutic strategies in the realm of targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 5-pyrrolidine-CHO is a conjugate designed for E3 ubiquitin ligase ligand-linker applications. This compound facilitates protein degradation by linking to E3 ligases, enabling targeted protein modulation. It serves as a valuable tool in the development and synthesis of novel bivalent degraders, such as NRX-0492. Researchers can utilize this compound for studies related to targeted therapeutics and protein homeostasis regulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-C-OH is an E3 ligase ligand-linker conjugate designed to target cereblon (CRBN). This compound facilitates the synthesis of PROTACs (Proteolysis Targeting Chimeras) by linking target proteins to the E3 ligase, promoting targeted degradation. Its key biological activity enhances protein modulation and offers significant potential for therapeutic applications in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide 5-fluoride 6-piperidine-C-OH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a functional linker. This compound is utilized in the synthesis of PROTACs, enabling targeted protein degradation through the modulation of E3 ligase activity. Its unique structure facilitates the development of novel therapeutic agents in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-(PEG2-amine) is an E3 ligase ligand-linker conjugate designed for use in the development of PROTACs (Proteolysis Targeting Chimeras). The compound features a terminal amine group that can undergo reaction with NHS esters or carboxylic acids in the presence of coupling agents such as EDC or HATU. The inclusion of a PEG spacer enhances the hydrophilicity and solubility in aqueous environments, making it suitable for biochemical applications and studies focused on targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-amide-C4-Br is an E3 ligase ligand-linker conjugate that incorporates a Pomalidomide-based ligand targeting cereblon (CRBN). This compound is utilized in the synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation and advancing studies in cellular regulation and therapeutic development. The incorporation of the linker facilitates the conjugation of E3 ligase components for efficient protein modulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-C-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand and a suitable linker. It is designed for the synthesis of PROTAC (Proteolysis Targeting Chimeras), enabling targeted degradation of specific proteins within the cell. This compound demonstrates significant potential in the fields of targeted protein degradation research and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-O-piperidin TFA is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC (proteolysis-targeting chimeras). This compound features a CRBN-based ligand linked to a piperidine moiety, facilitating targeted protein degradation. It serves as a valuable tool in chemical biology and drug discovery, particularly for studying protein regulation and therapeutic modulation of disease-related proteins. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-CH2-piperazine-C-COOH is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and a versatile linker. This compound is designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the selective degradation of target proteins. It enables research into targeted protein degradation mechanisms, offering insights for therapeutic developments. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-piperazine-azetidine TFA is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN)-based ligand and a piperazine-azetidine linker. It is designed for applications in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted protein degradation by recruiting E3 ligases, making it valuable for research in drug development and molecular biology studies focused on elucidating protein regulation and interactions. -
E3 Ligase Ligand-Linker Conjugates
Me-(S,R,S)-AHPC-PEG2-OTs is a conjugate designed for E3 ligase targeting within E3 Ligase Ligand-Linker Conjugates. This reagent facilitates the synthesis of PROTAC HIF-1α degrader-1, enabling studies in targeted protein degradation and cellular signaling pathways. Its application is essential for research focused on modulating protein levels through proteolysis-targeting chimera technology. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-propargyl-MeOH is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand and a propargyl linker. This compound is designed for the synthesis of PROteolysis TArgeting Chimeras (PROTACs), facilitating targeted protein degradation. Its application in biochemical research enables the investigation of protein dynamics and potential therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide 5'-piperazine-C1-piperidine hydrochloride is an E3 ligase ligand-linker conjugate targeting the cereblon (CRBN) protein. This compound facilitates the design and synthesis of PROTAC (Proteolysis Targeting Chimeras), which are valuable tools for targeted protein degradation research. Its unique properties enable scientists to investigate proteostasis and therapeutic strategies in various biological contexts. -
E3 ligase ligand-Linker Conjugate
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 is an E3 ligase ligand-linker conjugate that features the (4R,5S)-Nutlin carboxylic acid component, which targets MDM2. This compound enables the design of PROTACs by linking to a target protein, facilitating targeted protein degradation. It is particularly useful in research applications focused on modulating EZH2 levels and investigating E3 ligase functionalities in cellular systems. -
E3 Ligase Ligand-Linker Conjugate
tert-Butyl (trans-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)carbamate is an E3 ligase ligand-linker conjugate specifically designed for cellular protein degradation applications. This compound features a CRBN-based ligand and a flexible linker, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs). It is ideal for research investigating targeted protein degradation pathways and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-10-bromodecanoic acid is an E3 ligase ligand-linker conjugate that features a VHL ligand and a 10-bromo-decanoic acid linker. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by enabling targeted degradation of specific proteins. It is particularly applicable in the research of protein degradation pathways and the modulation of PI3Kδ activity for therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-F-C-piperazine is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs). Its unique chemical structure enables targeted degradation of specific proteins, making it a key tool in drug discovery and development, particularly in cancer research and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-pyrrolidine dihydrochloride is an E3 ligase ligand-linker conjugate specifically designed to target cereblon (CRBN). This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins through ubiquitin-proteasome pathways. Its application is crucial in chemical biology and drug discovery research, particularly for studying protein interactions and modulating cellular processes. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-azetidine-CHO is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound includes a cereblon (CRBN)-based ligand and a flexible linker, facilitating the synthesis of PROTACs (proteolysis-targeting chimeras). Its structural components enable effective modulation of protein levels in cellular environments, making it a valuable tool in biochemical research and drug development studies. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-O-7-azaspiro[3.5]nonane serves as an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) by linking a target protein with an E3 ubiquitin ligase. Its application in targeted protein degradation research underscores its potential to advance therapeutic strategies within the fields of oncology and cellular signaling. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-2,6-diazaspiro[3.3]heptane is an E3 ligase ligand-linker conjugate that utilizes a cereblon (CRBN)-based ligand. This compound is designed for the synthesis of proteolysis targeting chimeras (PROTACs), facilitating targeted protein degradation. Its unique structural features enhance the efficiency of ligand binding and promote the recruitment of E3 ligases for therapeutic strategies in various biological research areas. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C7-amine dihydrochloride functions as an E3 ligase ligand-linker conjugate, integrating the VH032-based VHL ligand with a tailored linker. This compound is specifically designed for use in PROTAC (proteolysis-targeting chimeras) applications, targeting the estrogen-related receptor α (ERRα) for degradation. Its unique structure enables enhanced selective degradation of ERRα, making it a valuable tool for research in targeted protein degradation and related cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 135 is a critical intermediate composed of an E3 ligase ligand and a linker, designed for use in the synthesis of complete PROTAC molecules. This compound facilitates the targeted degradation of proteins, specifically functioning in the context of the pan-KRAS degrader 5. It serves as a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-CH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC TEAD degrader-1, enabling the effective modulation of protein levels through the ubiquitin-proteasome system. Its utilization in various research settings aids in the study of protein interactions and degradation pathways, offering a valuable tool for advancing targeted therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C4-Boc is a conjugate that targets the E3 ligase Cereblon through an innovative linker. This compound facilitates the synthesis of PROTAC CARM1/IKZF3 degrader-1, enabling targeted protein degradation studies. Its primary application lies in the development of novel therapeutics and novel molecular probes in cellular research. -
E3 Ligase Ligand-Linker Conjugate
(S)-Thalidomide-5-fluoro-6-piperazin besylate functions as an E3 ligase ligand-linker conjugate, incorporating a cereblon (CRBN)-based ligand and linker. It is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation in cellular systems. This compound is valuable for research applications focused on protein regulation and therapeutic development in various disease models. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C7-Br is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound incorporates the Thalidomide-derived CRBN ligand along with a versatile linker, facilitating the synthesis of PROTAC constructs. Thalidomide-4-O-C7-Br serves as a crucial component for developing PROTACs aimed at promoting the degradation of specific proteins, such as FAK, thereby advancing research in cellular regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Pip-4-one is an E3 ligase ligand-linker conjugate that consists of a CRBN-based ligand and an optimized linker. This compound is utilized for the synthesis of Proteolysis Targeting Chimeras (PROTACs), which enable targeted protein degradation. Its applications in chemical biology facilitate the study of protein dynamics and the modulation of biological pathways in various research settings. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C5-Br is a synthetic E3 ligase ligand-linker conjugate that features a thalidomide-derived CRBN ligand combined with a versatile linker suitable for PROTAC applications. This compound facilitates the targeted degradation of specific proteins, exemplified by its role in the formation of PROTAC EZH2 Degrader-11. Thalidomide-4-O-C5-Br serves as a valuable tool for researchers investigating targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidin-piperazine is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand and a spacer. This compound is designed for the synthesis of protein-targeting chimeras (PROTACs), enabling the selective degradation of target proteins via the ubiquitin-proteasome system. Its use in research applications includes the investigation of targeted protein degradation mechanisms and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-piperazine-C-piperidine hydrochloride serves as an E3 ligase ligand-linker conjugate, incorporating a CRBN-based ligand and linker. This compound is designed for the synthesis of PROTAC (proteolysis-targeting chimeras), facilitating targeted protein degradation. Its utility lies in advancing research in therapeutic applications that involve modulation of protein homeostasis through targeted neosome pathways. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 4'-PEG6-azide is an E3 ligase ligand-linker conjugate designed for the targeted recruitment of the CRBN protein. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling selective protein degradation in cellular studies. Its application is essential in research focusing on the modulation of protein levels and the investigation of ubiquitin-proteasome pathways. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-O-piperidine is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC compounds. This reagent features a CRBN-based ligand linked to a piperidine moiety, enabling targeted recruitment of ubiquitin ligases for protein degradation studies. It is valuable for researchers exploring the therapeutic potential of targeted protein modulation and elucidating protein homeostasis mechanisms in various biological contexts.
